1. Home
  2. NCRA vs INDP Comparison

NCRA vs INDP Comparison

Compare NCRA & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.44

Market Cap

7.0M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.72

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
INDP
Founded
2002
2000
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
5.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
INDP
Price
$0.44
$1.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
82.0K
55.6K
Earning Date
04-01-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.52
52 Week High
$2.40
$47.60

Technical Indicators

Market Signals
Indicator
NCRA
INDP
Relative Strength Index (RSI) 30.04 35.69
Support Level $0.45 $1.62
Resistance Level $0.58 $2.66
Average True Range (ATR) 0.09 0.20
MACD 0.00 -0.05
Stochastic Oscillator 3.61 14.04

Price Performance

Historical Comparison
NCRA
INDP

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: